|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Mutational analyses identified somatic NRAS mutations in 2 primary melanomas, 4 melanoma metastases and 2 cell lines.
|
14961576 |
2004 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We have investigated 37 sporadic malignant melanomas (15 primary cutaneous melanomas and 22 melanoma metastases) and 6 melanoma cell lines for mutations in the 3 Ras genes NRAS, KRAS and HRAS.
|
14961576 |
2004 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overall, 40 of 47 (85%) melanoma cell lines and 11 of 16 (69%) uncultured melanoma metastases had mutations in NRAS, BRAF, or PTEN/MMAC1.
|
15009714 |
2004 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition, NRAS mutations were found in 2/11 (18.2%) CANs and 3/12 (25%) CMs.
|
15252839 |
2004 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In contrast, RNA interference directed at wild-type (WT) NRAS had no significant effect on apoptosis of 224 cells or 2 human melanoma cell lines (A375 and 397) containing WT NRAS but a codon 600 GTG (valine) to GAG (glutamate) mutation in BRAF.
|
15688405 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
These data suggest that oncogenic NRAS is important for avoidance of apoptosis in melanomas that harbor the codon 61 NRAS mutation and emphasizes oncogenic NRAS as a therapeutic target in patients with tumors that harbor this mutation.
|
15688405 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We screened 115 melanoma samples for the most common B-RAF and N-RAS mutations found in melanoma using a site-directed mutagenesis-based detection technique.
|
15737846 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results, though carried on cell lines, provide a novel insight into the effect of mutations in the B-RAF and N-RAS genes on global gene expression in melanoma and highlight the complexity of mechanisms involved in tumour initiation and maintenance.
|
15760917 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36).
|
15917418 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A B-RAF or N-RAS mutation was found in 8 of 23 (35%) spitzoid lesions suspected for melanoma.
|
16096402 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although BRAF and NRAS mutations are likely to be important for the initiation and maintenance of some melanomas, other factors might be more significant for proliferation and prognosis in subgroups of aggressive melanoma.
|
16098042 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Although BRAF and NRAS mutations are likely to be important for the initiation and maintenance of some melanomas, other factors might be more significant for proliferation and prognosis in subgroups of aggressive melanoma.
|
16098042 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, mutation of BRAF is highly frequent, and mutually exclusive mutations of BRAF and NRAS have also been reported in melanomas.
|
16273242 |
2005 |
|
melanoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Distinct sets of genetic alterations in melanoma.
|
16291983 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene.
|
16291983 |
2005 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, the authors evaluated the contribution of B-RAF and N-RAS mutations to the pathogenesis of Spitzoid melanomas.
|
16421887 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
These data suggest that NRAS and BRAF activating mutations can coexist in the same melanoma, but are mutually exclusive at the single-cell level.
|
16462768 |
2006 |
|
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
On the basis of our data showing that melanoma iNOS expression predicts shortened patient survival, we formulated the hypothesis that activating mutations of NRAS or BRAF, which lead to constitutive activation of the p44/42 MAPK pathway, drive iNOS expression in human melanoma.
|
16474847 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in BRAF and NRAS oncogenes in human melanomas are mutually exclusive.
|
16818621 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Mutations in NRAS were found in 5.2% of primary melanomas, 5.9% of nevi and no NRAS mutations were seen in in-situ melanomas.
|
16845322 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in NRAS were found in 5.2% of primary melanomas, 5.9% of nevi and no NRAS mutations were seen in in-situ melanomas.
|
16845322 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thus far, there is very limited data combining BRAF and NRAS mutation analysis to explore differences between cutaneous melanoma subtypes.
|
16899595 |
2006 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The most important signaling pathways in melanoma lie downstream of NRAS: the RAS-BRAF-MAPK pathway.
|
16901402 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We analyzed array comparative genomic hybridization data from 102 primary melanomas (38 from mucosa, 28 from acral skin, and 18 from skin with and 18 from skin without chronic sun-induced damage) for DNA copy number aberrations specific to melanoma subtypes where mutations in BRAF and NRAS are infrequent.
|
16908931 |
2006 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The impact of HRAS on the UPR was selective, as it was poorly induced by activated NRAS (more frequently mutated in melanoma than HRAS).
|
16964246 |
2006 |